Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNUG01 intrathecal gene therapy in adult ALS (Phase I/IIa, China)
ChiCTR2600117343Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SNUG01 in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Primary endpoints: Safety and Pharmacokinetic (PK) characteristics. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SNUG01
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2600117343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117343.